By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

EASD 2019 highlights

By Editor
24th September 2019
Cardiovascular disease, Care planning Education Good practice Type 1 diabetes Type 2 diabetes

New therapies and groundbreaking research into type 1 and 2 diabetes dominated this year’s European Association for the Study of Diabetes 2019 meeting. 

The event, which started on Tuesday, September 17, was held in Barcelona this year and attracted thousands of leading researchers and healthcare professionals from within the field of diabetes.

The European Association for the Study of Diabetes is a non-profit, medical scientific association and it aims to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

Over the course of the four day conference there were many interesting findings that were unveiled, here is a round up of some of them.

Poor diabetes control cost NHS £3 billion in 2017/18
Poor diabetes control cost the NHS £3 billion in potentially avoidable hospital treatment in England in 2017 and 2018, according to new research.

Data from the NHS Digital Hospital Episode Statistics in England and the National Diabetes Audit (2017–2018) was used to compare the costs of hospital care for 58 million people with and without diabetes.

The findings showed that on average, people with type 1 diabetes require six times more hospital treatment (£3,035 per person per year).

To read more, click here.

Linagliptin poses a “non-inferior risk” to cardiovascular health
Concerns about sulfonylureas’ cardiovascular safety have been put to rest after researchers unveiled new study findings which have shown linagliptin poses a “non-inferior risk” to cardiovascular health.

The ‘Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomised Clinical Trial‘ assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in newly diagnosed people with type 2 diabetes and risk factors for or established atherosclerotic cardiovascular disease.

Rates of major adverse cardiovascular events (MACE) did not differ significantly between the sulfonylurea glimepiride (Amaryl) and the DPP-4 inhibitor linagliptin (Tradjenta) in CAROLINA.

To read more, click here.

CGM shown to be beneficial in type 1 diabetes
Continuous glucose monitoring (CGM) was superior to self-monitoring of blood glucose for improving disease management in people with type 1 diabetes.

The COMISAIR real-world study found this benefit was independent of the patient’s insulin delivery method including multiple daily injections or insulin pump.

A total of 94 adults with type 1 diabetes were followed for three years. Those who used CGM saw significantly better HbA1c levels – 7% and 6.9% for the multiple daily injection and insulin pump groups, respectively – versus 7.7% and 8.0% for conventional self-monitors.

CGM users also saw significantly more time spent in range, as well as less time spent in hypoglycaemia.

To read more, click here.

Toddlers eating gluten raises type 1 diabetes risk
A child’s gluten intake at 18 months nearly doubles their risk of developing type 1 diabetes, according to new research.

The study showed that for 10g of gluten consumed by a toddler that raises the risk by 46%. However, no link was found between the mother’s intake of gluten during pregnancy and type 1 diabetes in her child.

Health data taken from 86,306 children born from 1999 to 2009 were used for this latest study. The outcome was clinical type 1 diabetes, ascertained in a nationwide childhood diabetes registry.

To read more, click here.

Early signs of adult type 2 visible in children as young as 8 years old
Early signs of adulthood type 2 diabetes can be seen in children as young as 8 years old, decades before it is likely to be diagnosed, according to new research.

A team from the University of Bristol analysed genetic information already known to increase the chances of type 2 diabetes in adulthood, together with measures of metabolism across early life.

They found that being more susceptible to adult diabetes affected a child’s levels of high-density lipoprotein (HDL), essential amino acids, and a chronic inflammatory trait measured in the blood.

Certain types of HDL lipids were among the earliest features of susceptibility to type 2 diabetes.

To read more, click here.

Global diabetes incidence declining
The diabetes incidence has either remained stable or decline in the majority of the world since 2006.

During these recent years, only 33% of the world had rising rates of new diabetes cases, mainly in the Pacific Islands, Middle East, and south Asia.

But this only came after a steep increase from 1990 through 2005, where 66% of the world’s populations saw increases in diabetes incidence, and only 2% saw a decline.

To read more, click here.

Obesity impacts type 2 risk
When it comes to risk factors for type 2 diabetes, obesity single-handedly dominates other factors including genetics and lifestyle.

Those with an “unfavourable” lifestyle had 18% higher risk (HR 1.18, 95% CI 1.06-1.30) for developing type 2 diabetes, and those with a high genetic risk score had doubled risk (HR 2.0, 95% CI 1.75-2.27) for incident type 2 diabetes.

But those with obesity had nearly sixfold higher risk (HR 5.81, 95% CI 5.16-6.55) during an average 15-year follow-up.

Most notably, adults who ranked high for all three risk factors — high genetic risk, unfavorable lifestyle, and obesity — had 14.5-fold higher risk for newly diagnosed diabetes (95% CI 8.09-26.13).

To read more, click here.

Comments (0)

Register an account or login to comment